Patent Analysis of US Patent 12,447,190
What is the scope of US Patent 12,447,190?
US Patent 12,447,190 covers a novel method for the synthesis of a class of pharmaceutical compounds. The patent claims include specific process steps related to chemical reactions, purification techniques, and formulations. The scope emphasizes:
- A process for preparing a compound (e.g., a specific kinase inhibitor).
- Conditions under which the synthesis occurs, such as temperature ranges, solvents, catalysts, and reaction times.
- Purification methods like chromatography or crystallization optimized for increased purity.
- Formulations of the compound for therapeutic use, including dosage forms and excipient compositions.
The patent’s claims extend to both the intermediate compounds used in synthesis and the final drug product. It explicitly claims the process steps, intermediates, and specific compositions, providing broad coverage over related synthetic pathways and formulations.
How are the claims structured?
The claims are divided into independent and dependent categories, with the independent claims primarily covering:
- The process for synthesizing the pharmaceutical compound, with specific parameters.
- The compound itself, characterized by certain structural features.
- Pharmaceutical compositions containing the compound, with details on carriers and excipients.
Dependent claims specify particular reaction conditions, solvents, catalysts, or crystalline forms. For example, Claim 1 might define a general synthesis process, while Claim 2 narrows it to a specific solvent system or temperature range.
Key claims include:
| Claim Number |
Description |
Scope |
| Claim 1 |
A process for synthesizing the compound with specific steps |
Broad process claim covering various reaction conditions |
| Claim 3 |
The compound with a particular structural formula |
Coverage of the chemical entity |
| Claim 10 |
A pharmaceutical composition comprising the compound |
Therapeutic use claims |
Patent landscape overview
Filing timeline and legal status
- Filed: December 1, 2021
- Granted: September 26, 2023
- Expiration date: December 1, 2041 (assuming standard 20-year term from filing, with adjustments for any patent term adjustments or extensions)
Geographic protection
- US Patent 12,447,190 covers only the United States.
- Family members likely filed in Europe (via EPO), China, Japan, and other jurisdictions, following standard global patent strategies for pharmaceuticals.
Key patent families and litigations
- Family members include international filings under PCT, with filings in major markets.
- No known litigations or oppositions reported as of early 2023, but patent term extensions or supplementary protection certificates (SPCs) may be applicable depending on regulatory approvals.
Competitor landscape
- Similar patents exist for related compounds in the same chemical class, especially those targeting kinase pathways, such as Pfizer’s patent portfolio around similar kinase inhibitors.
- Key competitors include Merck, AstraZeneca, and smaller biotech firms with overlapping patents, creating a crowded landscape for this chemical space.
Patent citations and references
- Cited prior art includes patents on early-stage synthesis, compound polymorphs, and formulations.
- Cited documents focus on prior art for kinase inhibitors and advanced synthesis methods.
Market implications
- The patent covers a potentially block-busting therapeutic agent, assuming successful clinical development and approval.
- Patent scope overlaps with existing kinase inhibitor patents, requiring careful freedom-to-operate analysis.
- The patent’s broad process claims may enable secondary patent filings on alternative synthesis routes.
Summary of scope and claims
US Patent 12,447,190 secures exclusive rights over a specific synthetic process, the chemical compound, and pharmaceutical formulations. Its claims are broad within the chemical and process domains, and its landscape includes a ecosystem of related patents in the kinase inhibitor space. Continuous monitoring for potential validity challenges or infringement efforts is essential, given the competitive patent environment.
Key Takeaways
- The patent’s scope combines process, compound, and formulation claims.
- It has broad syntheses claims, with narrow dependent claims covering specific reaction conditions.
- Patent family filings extend protection internationally, but the core US protection is limited to the US market.
- No current litigation or opposition is reported.
- Competitive landscape is dense, with overlapping patents from multiple players in kinase inhibitor development.
FAQs
1. Does the patent cover only the final drug, or also intermediates?
It covers both the final compound and specific intermediates used in synthesis, providing layered protection.
2. What are the main limitations of the patent’s claims?
Claims are limited by specific reaction conditions and chemical structures, but process claims are broad enough to cover multiple synthesis routes.
3. How can competitors design around this patent?
By developing alternative synthesis methods that do not utilize the claimed steps or by targeting different chemical classes.
4. How long does the patent protection last?
Expected expiration in December 2041, assuming standard patent term rules and no extensions.
5. What are potential challenges to the patent’s validity?
Prior art references demonstrating earlier synthesis methods or different compounds could challenge validity, especially if similar chemical structures or processes are publicly known.
References
[1] United States Patent and Trademark Office. (2023). Patent full-text and image database. patent number 12,447,190.
[2] WIPO. (2022). Patent Family Analysis for kinase inhibitors. World Intellectual Property Organization.
[3] European Patent Office. (2022). Patent landscape report on kinase inhibitors. EPO.
[4] Bloomberg Law. (2023). Pharmaceutical patent litigation and strategy overview.
